Erwinaze And The Blessings Of A Missed PDUFA Goal

By Bridget Silverman / Email the Author / Pharmaceutical Approvals Monthly January 2012, Vol. 17, No. 1
New Drug Approvals / Word Count: 927 / Article # 06120101015

Executive Summary

CDER missed one user fee goal for action in its 2011 novel approvals – EUSA Pharma’s Erwinaze – and running long allowed the agency and sponsor to find a work-around to a clinical problem that could otherwise have entailed time-consuming new investigations.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 927-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Erwinaze And The Blessings Of A Missed PDUFA Goal

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Pharmaceutical Approvals Monthly will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Erwinaze And The Blessings Of A Missed PDUFA Goal

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 2

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article